CanSino Biologics (6185) disclosed a third quarter 2025 report indicating that operating revenue for the nine months ended September 30, 2025 reached RMB692.57 million, reflecting a 22.13% year-on-year increase. Revenue for the July-September period grew to approximately RMB310.24 million, up 17.67% compared with the same period in 2024.

Net profit attributable to shareholders of the company turned around for the January-September period, reaching RMB14.44 million, while the figure for the third quarter alone was RMB27.93 million, an 842.01% increase year-on-year. Gross profit margin rose to 80.67% over the reporting period, boosted by higher vaccine production and continuous cost-reduction initiatives.

Research and development expenses totaled RMB274.16 million for the nine months, down 23.04% year-on-year, while net cash flow from operating activities turned positive at RMB33.49 million, supported by stronger sales of Menhycia® (MCV4 vaccine) and tighter expense controls. Total assets stood at RMB7.30 billion, and total owners’ equity attributable to the company reached RMB4.93 billion as of September 30, 2025.